STOKE THERAPEUT.DL-001
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-… Read more
STOKE THERAPEUT.DL-001 (0GT) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, STOKE THERAPEUT.DL-001 (0GT) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
STOKE THERAPEUT.DL-001 - Net Assets Trend (None–None)
This chart illustrates how STOKE THERAPEUT.DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for STOKE THERAPEUT.DL-001 (None–None)
The table below shows the annual net assets of STOKE THERAPEUT.DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to STOKE THERAPEUT.DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
STOKE THERAPEUT.DL-001 Competitors by Market Cap
The table below lists competitors of STOKE THERAPEUT.DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Thermax Limited
NSE:THERMAX
|
$1.22 Billion |
|
Toei Animation Co.Ltd
OTCGREY:TOEAF
|
$1.22 Billion |
|
Guangdong Rongtai Industry Co Ltd
SHG:600589
|
$1.22 Billion |
|
Batisoke Soke Cimento Sanayi TAS
IS:BSOKE
|
$1.22 Billion |
|
Hoshizaki Corporation
PINK:HSHZY
|
$1.22 Billion |
|
Quidel Corporation
NASDAQ:QDEL
|
$1.22 Billion |
|
KEYMED BIOSCIENCES -0001
F:64Z
|
$1.22 Billion |
|
Chongqing Iron & Steel Co Ltd Class A
SHG:601005
|
$1.22 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in STOKE THERAPEUT.DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares STOKE THERAPEUT.DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently STOKE THERAPEUT.DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares STOKE THERAPEUT.DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| STOKE THERAPEUT.DL-001 (0GT) | €- | N/A | N/A | $1.22 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |